|
Array BioPharma is discovering it's best to be your own boss. Once devoted to discovering drug candidates for other firms, the company is increasingly focused on its own drug development efforts in the areas of cancer and inflammatory disease. Candidates in early clinical trials include potential therapies for breast cancer (ARRY-543) and rheumatoid arthritis (ARRY-162). Array has also out-licensed some cancer programs to AstraZeneca and Genentech; ARRY-886, developed with AstraZeneca, is in clinical trials for melanoma. Drug discovery services for third parties still account for a big chunk of business; Array has R&D agreements with InterMune, Ono Pharmaceutical, Celgene, and others.
|
| | | Contact Information | |
Address: |
3200 Walnut St.
Boulder, CO 80301
| | Phone: | 303-381-6600 | | Fax: | 303-386-1390 |
|
| Financial
Highlights | | Fiscal Year End: | June | | Revenue (2009): | 25.00 M | | Revenue Growth (1 yr): | (-13.30%) | | Employees (2009): | 355 | | Employee Growth (1 yr): | (-8.00%) |
|
|
Key People
| | • |
Chairman:
Kyle A. Lefkoff
| | • |
CEO and Director:
Robert E. (Bob) Conway
| | • |
President, Chief Scientific Officer, and Director:
Kevin Koch
|
|
|
